Aromatase inhibitors, including letrozole, have been evaluated primarily in postmenopausal women or those with obesity-related EH, demonstrating reductions in endometrial thickness and symptomatic improvement in small studies of 20–40 patients; however, long-term safety data remain limited. Here, CYP19A1 is linked to Obesity.